Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Sol-Gel Technologies Ltd ownership disclosure: Opaleye Management Inc., Opaleye, L.P. and James Silverman report beneficial ownership of 460,335 Ordinary Shares, representing 16.52% of the class. The filing states 2,786,158 Ordinary Shares outstanding as of December 31, 2025.
The statement clarifies the Adviser (Opaleye Management Inc.) advises the Fund (Opaleye, L.P.), Mr. Silverman controls the Adviser, and the reported shares are directly held by the Fund. Signatures show Mr. Silverman signed in multiple capacities.
Sol-Gel Technologies Ltd. filed Post-Effective Amendment No. 4 converting its prior Form F-1 registration into a Form F-3 and incorporating its audited financial results for the fiscal year ended December 31, 2025. The amendment does not register any additional securities.
Offering details: the prospectus covers resale by selling shareholders of up to 656,000 ordinary shares (par value NIS 1.0), comprised of 256,000 Investor Warrant Shares, 200,000 Affiliate Shares and 200,000 Affiliate Warrant Shares. Ordinary shares outstanding were 2,809,879 as of March 18, 2026 and would be 3,265,879 assuming issuance of the referenced warrant shares. The company will not receive proceeds from resale transactions, but may receive up to $26,676,000 assuming full cash exercise of the warrants, which the prospectus states would be used for general corporate purposes.
Sol-Gel Technologies Ltd. files its annual report on Form 20-F, detailing a specialty dermatology business that remains deeply loss-making and high risk. The company reported net losses of $27.2M in 2023, $10.6M in 2024 and $6.1M in 2025, leading to an accumulated deficit of $237M as of December 31, 2025.
The auditors included a going-concern explanatory paragraph, reflecting substantial doubt about Sol-Gel’s ability to continue operating without additional capital. Operations have been funded mainly through equity offerings and loans from the controlling shareholder, and management expects significant further losses as it develops SGT-610 and other candidates.
Sol-Gel has FDA-approved products Twyneo and Epsolay but sold its U.S. rights to Mayne in April 2025 for up to $16M in upfront and milestone payments, and relies on license partners in Canada, China and other territories. All current pipeline products remain in development and face extensive clinical, regulatory, funding and commercialization risks.
Sol-Gel Technologies Ltd. executive Yosef Itzik, the Chief Operating Officer, reported his initial beneficial ownership of stock options on Ordinary Shares. He holds options over 2,031 Ordinary Shares at an exercise price of 100.0000 per share, expiring on March 29, 2032.
He also holds options over 566 Ordinary Shares at an exercise price of 56.0000 per share, expiring on March 9, 2033, and 499 Ordinary Shares at an exercise price of 8.9600 per share, expiring on February 18, 2035. The footnotes describe vesting schedules where 25% of each grant vests on a specified initial date, with the remaining portion vesting in equal quarterly installments, subject to his continued service.
Sol-Gel Technologies Ltd. Chief Financial Officer Eyal Ben-Or filed an initial ownership report showing direct holdings of 1,000 Ordinary Shares and several stock option awards. These include options over 7,500 Ordinary Shares at an exercise price of 69.5000 per share, expiring on January 19, 2036. Footnotes state that some options are fully vested, while others vest 25% on specified dates and then in equal quarterly installments over three years, subject to his continued service.
Sol-Gel Technologies Ltd. director Gottfried Ran filed an initial Form 3 showing his equity stake in the company. He directly holds 1,550 Ordinary Shares and two stock option grants over 4,500 and 7,500 Ordinary Shares, with exercise prices of 100.2000 and 12.0000, expiring on February 2, 2031 and January 9, 2034, respectively.
One option is fully vested, while the other vested 33.33% on February 28, 2025 and continues to vest in equal quarterly installments over two years, subject to his continued service as a director.
Sol-Gel Technologies Ltd. director Sharon Kochan reported existing derivative holdings in an initial ownership statement. The filing lists a stock option to buy 7,500 Ordinary Shares at an exercise price of $12.0000 per share, expiring on January 9, 2034.
The option vested as to 33.33% of the underlying Ordinary Shares on February 28, 2025 and is scheduled to vest in equal quarterly installments over the following two years, conditioned on continued service as a director. All 7,500 underlying shares are reported as directly held through this option position.
Sol-Gel Technologies Ltd. director Yanai Yuval has reported initial beneficial ownership of a stock option to buy Ordinary Shares. The option covers 7,500 underlying Ordinary Shares at an exercise price of $12.0000 per share and expires on January 9, 2034.
According to the vesting terms, 33.33% of the option vested on February 28, 2025, with the remaining Ordinary Shares vesting in equal quarterly installments over the following two years, subject to his continued service as a director.
Sol-Gel Technologies Ltd. director Hanna Lerman reports holding a fully vested stock option to buy 2,031 ordinary shares at an exercise price of 55.6600. The option relates to ordinary shares with NIS 1.00 par value per share and expires on 2027-07-13.